Long-Acting Breakthrough

In a more bullish outcome, Nanexa's technology produces convincing pharmacokinetic data that allows Novo to credibly pursue monthly or less-frequent obesity injections. This would strengthen Novo's lifecycle-management strategy against Zepbound, VK2735, and future oral obesity drugs.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.